Podcasts about Wolters Kluwer

By Adam Turteltaub The rise of generative AI has brought transformative potential to healthcare—from streamlining administrative tasks to supporting clinical decision-making. But alongside these benefits comes a growing concern: Shadow AI. Alex Tyrrell, Chief Technology Officer, Health at Wolters Kluwer explains in this podcast that this term refers to the use of unauthorized, unmonitored AI tools within organizations. In healthcare, where data privacy and patient safety are paramount, Shadow AI presents a unique and urgent challenge both now and in the future. Healthcare professionals often turn to generative AI tools with good intentions—hoping to reduce documentation burdens, improve workflows, or gain insights from complex data. However, many of these tools are unproven large language models (LLMs) that operate as black boxes. They're prone to hallucinations, lack transparency in decision-making, and may inadvertently expose Protected Health Information (PHI) to the open internet. This isn't just a theoretical risk. The use of public AI tools on personal devices or in clinical settings can lead to serious consequences, including: Privacy violations Legal and regulatory non-compliance Patient harm due to inaccurate or misleading outputs Despite these risks, many healthcare organizations lack visibility into how and when these tools are being used. According to recent data, only 18% of organizations have a formal policy governing the use of generative AI in the workplace, and just 20% require formal training for employees using these tools. It's important to recognize that most employees aren't using Shadow AI to be reckless—they're trying to solve real problems. The lack of clear guidance, approved tools, and education creates a vacuum that Shadow AI fills. Without a structured approach, organizations end up playing a game of whack-a-mole, reacting to issues rather than proactively managing them. So, what can healthcare organizations do to address Shadow AI without stifling innovation? Audit and Monitor Usage Start with what you can control. For organization-issued devices, conduct periodic audits to identify unauthorized AI usage. While personal devices are harder to monitor, you can still gather feedback from employees about where they see value in generative AI. This helps surface use cases that can be addressed through approved tools and structured programs. Procure Trusted AI Tools Use procurement processes to source AI tools from vetted vendors. Look for solutions with: Transparent decision-making processes Clear documentation of training data sources No use of patient data or other confidential information for model training Avoid tools that lack explainability or accountability—especially those that cannot guarantee data privacy. Establish Structured Governance Governance isn't just about rules—it's about clarity and oversight. Develop a well-articulated framework that includes: Defined roles and responsibilities for AI oversight Risk assessment protocols Integration with existing compliance and IT governance structures Make sure AI governance is not siloed. Those managing AI tools should be at the table during strategic planning and implementation. Educate and Engage Education is the cornerstone of responsible AI use. Employees need to understand not just the risks, but also the right way to use AI tools. Offer formal training, create open forums for discussion, and build a culture of transparency. When people feel informed and supported, they're more likely to choose safe, approved tools. Protect PHI with Precision In clinical workflows, PHI is often unavoidable. That's why it's critical to: Deidentify patient data whenever possible Ensure only authorized systems, processes, and personnel have access to PHI Maintain up-to-date business associate agreements and data processing contracts

Welcome to PsychEd, the psychiatry podcast for medical learners, by medical learners. This short episode covers how to take a substance use historyHosts: Dr. Andrew Nguyen, Dr. Zakia Hussain, Jo Kikukawa, and Dr. Kate Braithwaite.Audio editing: Dr. Kate BraithwaiteResources:Chapter 4: Substance Use and Addictive Disorders. In Kaplan & Sadock's Synopsis of Psychiatry: Behavioral SciencesMeta:Phi Resource LibraryTen Domains of De-escalation to Prevent Behavioural Emergencies (from Alberta Health Services)References:American Psychiatric Association Publishing. (2022). Substance-Related and Addictive Disorders. In Diagnostic and Statistical Manual of Mental Disorders: Fifth Edition, Text Revision: DSM-5-TR (5th ed., pp. 481-590). American Psychiatric Association Publishing. Boland, R.J., Verduin, M.L., & Ruiz, P. (2022). Chapter 4: Substance Use and Addictive Disorders. In Kaplan & Sadock's Synopsis of Psychiatry: Behavioral Sciences, Clinical Psychiatry (12th ed., pp. 269 - 336). Wolters Kluwer. Porter, L.D. Getting to the Good Part: How to Take an Engaging SUD History. [Presentation Transcript]. University of California, Los Angeles Integrated Substance Use and Addictions Programs. https://www.uclaisap.org/clinicalproviderquicktips/docs/La-Donna-Porter/Porter_LD_Transcript_Clean.pdf Welsh, C.J. “Trapped”: A Mnemonic for Taking a Substance Use History. Acad Psychiatry 27, 289 (2003). https://doi.org/10.1176/appi.ap.27.4.289For more PsychEd, follow us on Instagram (⁠@psyched.podcast⁠),  Facebook (⁠PsychEd Podcast⁠), X (⁠@psychedpodcast⁠), and Bluesky (⁠@psychedpodcast.bsky.social‬⁠). You can email us at ⁠psychedpodcast@gmail.com⁠ and visit our website at⁠ ⁠⁠psychedpodcast.org⁠.

Afgelopen beursweek was een interessante. Er was veel beweging in de koersen van individuele aandelen. Een aantal zakte volledig door het ijs. Duolingo, Wolters Kluwer en Adobe werden bijvoorbeeld genadeloos afgestraft. Op het eerste gezicht hebben deze bedrijven weinig met elkaar te maken, maar hun koers staat dit jaar grofweg een procent of veertig in het rood. Ze worden allemaal gezien als ondernemingen waarvan het bedrijfsmodel door het gebruik van AI onder druk komt te staan. Terwijl ze een tijd geleden juist werden gezien als bedrijven die daar sterk van zouden profiteren. Zo kan Duolingo kunstmatige intelligentie gebruiken om veel efficiënter te worden. Maar nu zijn beleggers juist gefocust op AI-concurrenten zoals Anki, Memrise en LingQ. Ik probeer al tijden mijn Spaans wat op te kalefateren, dus wellicht moet ik die eens proberen. Want Duolingo is grappig, maar brengt je niet echt dichter bij het voeren van een normaal gesprek. Voor de medische database van Wolters Kluwer zijn er goedkope alternatieven, zoals OpenEvidence en ClinicalKey. Die zouden volgens de verhalen flink aan de weg timmeren en de bijna-monopoliepositie van Wolters Kluwer ondermijnen. Maar ja, ik ken geen dokters in de VS, dus ik kan moeilijk bepalen of dat echt zo is, of niet. Goede informatie is essentieel voor een arts. Wil je het risico lopen om medisch advies te krijgen van een hallucinerend AI-model? Zijn die verhalen ruis, of een signaal? Andersom gebeurt het ook. Eerder dit jaar dachten beleggers dat Googles advertentie-inkomsten gingen doodbloeden. Alle zoekopdrachten zouden met AI-modellen worden gedaan, en dan hoef je niet meer langs de reclames, waar het bedrijf $265 mrd van zijn totale $350 mrd aan omzet uit haalt. De waardering van Google kelderde van 23 naar 16 maal de verwachte winst, maar inmiddels zijn deze angsten overgewaaid en staat het aandeel weer op een k/w van 26. Aangezien de verwachte winsten verder zijn gestegen, betekent dat een verdubbeling van de koers in een half jaar tijd. Om de schrijver Mark Twain te parafraseren: de berichten over Googles dood zijn schromelijk overdreven. Het bijzondere is de draai in de perceptie van beleggers. De ene keer zijn ze erg enthousiast over de AI-impact, de andere keer juist erg somber. Jantje huilt, Jantje lacht. Bedenk wel dat technologische ontwikkelingen hele bedrijven onderuit hebben gehaald, zoals Nokia, Blackberry, Xerox en Kodak. Je moet dus ruis en signaal van elkaar kunnen onderscheiden. De conclusie is simpel. Het is voor beleggers essentieel om te bepalen in hoeverre een bedrijf echt wordt geraakt door de AI-ontwikkelingen en in hoeverre het slechts een verhaal is. Als het lukt om ruis van signaal te scheiden, kun je hele mooie bedrijven voor een prikkie kopen. Maar pas wel op dat je geen Kodak-momentje hebt. Corné van Zeijl is analist en strateeg bij Cardano en belegt ook privé. Reageer via c.zeijl@cardano.com. Deze column kun je ook iedere donderdag lezen in het FD.See omnystudio.com/listener for privacy information.

Afgelopen beursweek was een interessante. Er was veel beweging in de koersen van individuele aandelen. Een aantal zakte volledig door het ijs. Duolingo, Wolters Kluwer en Adobe werden bijvoorbeeld genadeloos afgestraft.

Rendement, rendement, elke belegger heeft het erover maar: waar komt het precies vandaan? In deze aflevering zoeken we het uit tot op de bodem. Van omzetgroei, via winst per aandeel, naar de multiple. Want we hebben het wel altijd over fundamentele eigenschappen van bedrijven, maar de invloed van wat de markt bereid is te betalen moet je ook niet onderschatten. Om dat te illustreren, voorbeelden die je van je stoel doen vallen: Fair Isaac en Wolters Kluwer enerzijds, en Adyen anderzijds. Plus een rondje langs big tech. ► Uitgebreide show notes en achtergrondinformatie: https://jongbeleggendepodcast.nl/206-waar-komt-je-rendement-vandaan ► Word Vriend: https://portfoliodividendtracker.com ► Updates via Instagram: https://www.instagram.com/jongbeleggen ► Mijn volledige portfolio: https://app.portfoliodividendtracker.com/p/jongbeleggen 1) We maken gebruik van programmatic advertising, wat inhoudt dat we geen invloed hebben op de spots die in de podcast worden afgespeeld. Dit is vergelijkbaar met tv, YouTube, radio en de krant, uiteraard met uitzondering van de advertenties die we zelf hebben ingesproken. 2) Deze podcast is 100% expertise-vrij en alleen geschikt voor amusementsdoeleinden. De inhoud mag niet worden beschouwd als financieel advies. ► Voor boekhoudtips én een extra lange gratis proefperiode, ga naar moneybird.nl/jongbeleggen. ► Beveilig je online leven met Surfshark VPN! Ga naar https://surfshark.com/jongb of gebruik de code JONGB voor 4 extra maanden Surfshark. Geld-terug-garantie van 30 dagen inbegrepen. ► Geef jezelf 3 tellen en bij twijfel klik weg. Deze aflevering is in samenwerking met De Rijksoverheid. Kijk voor meer informatie over online oplichting op laatjenietinterneppen.nl.See omnystudio.com/listener for privacy information.

In this episode, Dr. Peter Bonis, Chief Medical Officer at Wolters Kluwer Health, discusses the opportunities and risks of using AI in clinical care. He highlights the importance of accuracy, governance, and frontline engagement to ensure technology supports safe and effective decision-making for patients and providers.This episode is sponsored by Wolters Kluwer.

In this week's episode of Dividend Talk we kick off with Kimberly-Clark's surprise move to buy Kenvue, asking if it's a smart acquisition or a future balance-sheet headache. Then we review Q3 earnings from Novo Nordisk, Wolters Kluwer, and Ahold Delhaize, three European dividend powerhouses facing very different challenges.Novo Nordisk's obesity drugs, valuation reset, and dividend safety dominate the discussion, while Wolters Kluwer's high-PE sell-off and the impact of AI on research businesses spark debate on fair value and buybacks. We also look at Snap-on's double-digit dividend hike and Simon Property Group's steady income growth for REIT investors.Later, we revisit our “Monthly Dividend Portfolio” challenge from 2022, checking how picks like Altria, AbbVie, Johnson & Johnson, Realty Income, Shell, and Texas Instruments performed with lessons on dividend growth, yield, and diversification.In the listener Q&A, we cover:Dividend tax strategies and EU exit taxes How to handle rising wealth taxes as a dividend investor Fair-value analysis vs Morningstar valuations Our take on Volkswagen, General Mills, GreenCoat UK, ExxonMobil vs Chevron, and the global renewable-energy transition Thoughts on Unilever's upcoming Magnum spinoff SEE YOU ON THE INSIDE!!Tickers discussed: KMB, KVUE, NVO, LLY, PFE, WKL.AS, AD.AS, SNAP-ON, SPG, MO, ABBV, JNJ, O, TXN, SHEL, GIS, XOM, CVX, UKW.LJoin us:[Facebook] – Https://www.facebook.com/groups/dividendtalk⁠[Twitter] – @DividendTalk_ , @European_DG[Discord] – ⁠https://discord.gg/nJyt9KWAB5⁠[Premium Services] – ⁠https://dividendtalk.eu/download-your-free-samples/⁠[Malmo Meetup] – ⁠https://t.co/STgV1nMWKj

Waaron zijn analisten en experts zoveel pessimistischer over de beleggingsvooruitzichten dan particuliere beleggers? En wie hebben er gelijk?In de IEX Beleggerspodcast ontvangt gastheer Pieter Kort beursexpert Corné van Zeijl en IEX-analist Martin Crum, en gaat op zoek naar het antwoord op deze en andere beleggingskwesties. In deze aflevering:De kleine buy-the-dip-belegger snapt de huidige markt soms beter dan de professionalsDe favoriete aandelen van de pro's en van het brede publiek   De fabelachtige rendementen van congreslid Nancy PelosiHoe komt OpenAI aan zijn investeringsgeld?Luisteraarsvraag: wat zou ASML waard zijn als het een Amerikaans bedrijf was?Aandelen: Amazon, Philips, KPN, Wolters Kluwer, Pharming, Heineken en AB InbevETF's: Welke ETF zou je nu kopen om een jaar op de plank te leggen?

Meer informatie over de Optie opleiding met optie-expert Vincent Vis: https://www.deaandeelhouderacademy.nl/ontdek-de-kracht-van-veilige-optiehandel/Meer informatie over de Dividend opleiding met Albert Jellema en Jean-Paul van Oudheusden:https://www.deaandeelhouderacademy.nl/dividend-beleggen-in-een-dag/Nu lid worden van DeAandeelhouder Pro? Ga naar:https://www.deaandeelhouder.nl/login/?redirect_to=https://www.deaandeelhouder.nl/mijn-account/pro/Lid worden van ProBeleggen? Ga naar: https://www.probeleggen.nl/aanmelden/registreren/  Lid worden van de aandeelhouder? Ga naar: https://www.deaandeelhouder.nl/premium/In de wekelijkse podcast van DeAandeelhouder ontvangt deze week Nico Inberg diverse experts uit de financiële wereld om te praten over de beurs, beleggen en aandelen. Deze week verwelkomen wij Erik Mauritz van Trade Republic. Onderwerpen die aan bod komen zijn Ahold Delhaize, Novo Nordisk, Palantir, KPN, Wolters Kluwer, Vopak & veel meer!Volg DeAandeelhouder op andere kanalen:Website: https://www.deaandeelhouder.nl/Twitter (X):  https://twitter.com/deaandeelhouderTikTok:  https://www.tiktok.com/@deaandeelhouderInstagram:  https://www.instagram.com/deaandeelhouder/Facebook: https://www.facebook.com/DeAandeelHouder/LinkedIn: https://www.linkedin.com/company/de-aandeelhouder-nl/Tijdslijn:00:00 - 7:00 Verbazing van de week7:00 - 12:20 Michael Burry & Palantir12:20 - 17:50 AI investeringen17:50 - 19:45 Ahold Delhaize19:45 - 22:45 Wolters Kluwer22:45 - 28:40 Novo Nordisk28:40 - 31:15 Bitcoin31:15 - 33:00 ForFarmers33:00 - 35:50 Pharming35:50 - 41:10 CM.com41:10 - 45:03 Macro45:03 - 50:10 Vopak50:10 - 52:05 KPN52:05 - 54:03 IMCD & Azelis54:03 Trade Republic & vooruitblikOntvang al onze exclusieve analyses, video's en beurscontent:https://www.deaandeelhouder.nl/premium/Met een premium abonnement krijgt u wekelijks exclusieve video's en uitleg over potentieel koopwaardige aandelen, regelmatig artikelen met tips om op een verstandige manier met uw geld om te gaan, verder krijgt u tweewekelijks toegang tot de chatsessie met Nico Inberg en als klap op de vuurpijl krijgt u iedere zaterdag ons online magazine. Een kleine investering, voor een veel mooier rendement.

Ja, de outlook is verlaagd en ja, de koers is vanaf de top 70 procent gedaald. Toch is Stan Westerterp van Bond Capital Partners positief over de Deense farmaceut. "Er is nog steeds sprake van groei, zowel van de operationele winst als de winst per aandeel. Ook de omzet steeg met 12 procent." Stan heeft voor zijn klanten de positie in Novo Nordisk dan ook uitgebreid. De onderliggende markt is gigantisch en er is nog een enorm potentieel. Zo kijkt Robbert Manders van het Antaurus Europe Fund er ook naar. "Het is een bedrijf met een paar mooie patenten en het geen dure farmaceut meer. Er zijn nog veel landen die kunnen beginnen met het vergoeden van Ozempic." Dat geeft wel aan dat er voldoende potentieel is voor Novo Nordisk. Ook voor Pharming zijn er lovende woorden. Dat aandeel is in een jaar tijd met 90 procent gestegen, wat niet gek is na - wederom - een verhoging van de omzetdoelstelling. De dure medicijnen, waar patiënten langdurig gebruik van maken, vinden steeds meer hun weg naar de markt. Verder in deze aflevering aandacht voor onder andere Ahold Delhaize, Philips, Wolters Kluwer en Palantir. De luisteraarsvragen komen aan bod en de experts geven hun tips. Stan tipt een Deens en een Nederlands bedrijf, Robbert tipt deze keer een Zwitsers aandeel. Geniet van de podcast! Let op: alleen het eerste deel is vrij te beluisteren. Wil je de hele podcast (luisteraarsvragen en tips) horen, wordt dan Premium lid van BeursTalk. Dat kost slechts 9,95 per maand, 99 euro voor een heel jaar. Abonneren kan hier!See omnystudio.com/listener for privacy information.

Ahold Delhaize overtreft de verwachting van analisten. De winst én omzet vallen in het derde kwartaal hoger uit. Het bedrijf gaat daarom (opnieuw) eigen aandelen inkopen. Voor 1 miljard euro. Ook investeert het supermarktbedrijf in AI. Deze aflevering hebben we het over die stap. Gaat het Ahold verder helpen? De marges verbeteren nu al, maar kunnen misschien nóg meer groeien. Hebben we het ook over de Amerikaanse shutdown. Dat is nu officieel de langste uit de Amerikaanse geschiedenis. Al 36 dagen zit de boel daar op slot en een einde is nog lang niet in zicht. Wij proberen te kijken wat dat betekent voor de Amerikaanse economie, voor de beurs en voor jou als belegger.Een shutdown die de beursgang van The Magnum Ice Cream Company in de war schopte. Die werd vertraagd, maar er kwam vandaag toch goed nieuws. Op 8 december gaat de ijsjestak alsnog naar de beurs van New York, Londen én Amsterdam! Kwartaalcijfers zijn er ook van Toyota, Novo Nordisk en Wolters Kluwer. We vertellen je waar je op moet letten. Waarom de cijfers van McDonalds zo goed zijn én over een Nederlands beursbedrijf dat mogelijk het Damrak gaat verlaten.See omnystudio.com/listener for privacy information.

Ahold Delhaize overtreft de verwachting van analisten. De winst én omzet vallen in het derde kwartaal hoger uit. Het bedrijf gaat daarom (opnieuw) eigen aandelen inkopen. Voor 1 miljard euro. Ook investeert het supermarktbedrijf in AI. Deze aflevering hebben we het over die stap. Gaat het Ahold verder helpen? De marges verbeteren nu al, maar kunnen misschien nóg meer groeien. Hebben we het ook over de Amerikaanse shutdown. Dat is nu officieel de langste uit de Amerikaanse geschiedenis. Al 36 dagen zit de boel daar op slot en een einde is nog lang niet in zicht. Wij proberen te kijken wat dat betekent voor de Amerikaanse economie, voor de beurs en voor jou als belegger.Een shutdown die de beursgang van The Magnum Ice Cream Company in de war schopte. Die werd vertraagd, maar er kwam vandaag toch goed nieuws. Op 8 december gaat de ijsjestak alsnog naar de beurs van New York, Londen én Amsterdam! Kwartaalcijfers zijn er ook van Toyota, Novo Nordisk en Wolters Kluwer. We vertellen je waar je op moet letten. Waarom de cijfers van McDonalds zo goed zijn én over een Nederlands beursbedrijf dat mogelijk het Damrak gaat verlaten.See omnystudio.com/listener for privacy information.

Het cijferseizoen loopt op z'n eind, maar vervelen hoef je je nog niet. Wij richten ons deze week eens puur op Nederlandse bedrijven. Want Bob Homan van ING Investment Office gaat letten op: Wolters Kluwer, Ahold Delhaize en Phillips. Hij vertelt waarom hij vooral op Wolters Kluwer gaat letten. Een aandeel dat gigantisch afgestraft is en dat vooral door een leiderswissel.Ook gaat het over het belang van voedselbonnen voor de kas van Ahold en de (toezicht)problemen van Philips. In Beurs in Zicht stomen we je klaar voor de beursweek die je tegemoet gaat. Want soms zie je door de beursbomen het beursbos niet meer. Dat is verleden tijd! Iedere week vertelt een vriend van de show waar jouw focus moet liggen.See omnystudio.com/listener for privacy information.

Het cijferseizoen loopt op z'n eind, maar vervelen hoef je je nog niet. Wij richten ons deze week eens puur op Nederlandse bedrijven. Want Bob Homan van ING Investment Office gaat letten op: Wolters Kluwer, Ahold Delhaize en Phillips. Hij vertelt ons waarom alle drie de bedrijven te maken hebben met tegenwind en hoe je daar als belegger mee om moet gaan.

Het cijferseizoen loopt op z'n eind, maar vervelen hoef je je nog niet. Wij richten ons deze week eens puur op Nederlandse bedrijven. Want Bob Homan van ING Investment Office gaat letten op: Wolters Kluwer, Ahold Delhaize en Phillips. Hij vertelt waarom hij vooral op Wolters Kluwer gaat letten. Een aandeel dat gigantisch afgestraft is en dat vooral door een leiderswissel.Ook gaat het over het belang van voedselbonnen voor de kas van Ahold en de (toezicht)problemen van Philips. In Beurs in Zicht stomen we je klaar voor de beursweek die je tegemoet gaat. Want soms zie je door de beursbomen het beursbos niet meer. Dat is verleden tijd! Iedere week vertelt een vriend van de show waar jouw focus moet liggen.See omnystudio.com/listener for privacy information.

While the year-over-year figure reflects broader market volatility, Matthew Babcock, who oversees digital lending product strategy for Wolters Kluwer, explained the strong quarter-over-quarter increase of the Q3 Wolters Kluwer Auto Finance Digital Transformation Index signals market re-engagement. Babcock elaborated about these points and more during an episode of the Auto Remarketing Podcast.

In this episode, Yaw Fellin, Senior Vice President and General Manager, Clinical Decision Support and Provider Solutions, Wolters Kluwer Health discusses how clinical intelligence and AI are transforming care delivery, the importance of transparency, expert oversight, and governance in trustworthy AI adoption, and how organizations can experiment responsibly to improve outcomes and clinician support.This episode is sponsored by Wolters Kluwer.

What happens when an AI strategy meets the real-world complexity of healthcare, law, and finance? That's the challenge at the heart of my conversation with Mark Sherwood, CIO of Wolters Kluwer, a global leader in professional information services. With over three decades in technology leadership across Microsoft, Symantec, and Nuance, Mark brings a rare combination of enterprise depth and hands-on pragmatism to the AI discussion. Mark explains why cloud-native architecture and data governance are the twin foundations of trustworthy AI. He shares how Wolters Kluwer is embedding AI across highly regulated industries—from helping doctors access life-saving insights through natural language queries to giving tax and legal professionals faster, more accurate guidance on complex regulations. Behind the innovation lies a disciplined approach: governing data, managing risk, and building confidence in AI systems that must meet the highest standards of accuracy and compliance. We also explore how to build high-trust, low-friction partnerships between IT and business teams to prevent shadow IT while accelerating digital transformation. Mark offers candid insights into the rise of AI agents, the emerging risks of quantum security, and why he believes that high-quality data is the most valuable currency in digital transformation. His philosophy is simple: speed means nothing without trust, and trust starts with clean, well-governed data. From cloud transformation to the future of AI regulation, this episode offers a grounded look at how global enterprises can scale responsibly in an era where innovation often outruns policy. So as AI becomes inseparable from how professionals think and work, how do we balance speed with stewardship? And are we truly ready for the ethical, technical, and quantum frontiers ahead? Share your thoughts after the episode.

On the 57th episode of Enterprise AI Innovators, host Evan Reiser (Abnormal AI) talks with Mark Sherwood, EVP & CIO at Wolters Kluwer. Mark shares how his team is applying AI across internal operations and product development. From automating SOP creation to surfacing risk in contracts and predicting IT incidents, each project starts with a specific business challenge and ends with a measurable impact. Wolters Kluwer now sees over half of its revenue from AI-enabled products, a result of decades of domain expertise paired with rapid experimentation.Quick hits from Mark: On AI-generated SOPs: “It used to take two or three weeks to finalize and get it done. Now, it's essentially 15 minutes, worst case, probably two minutes, best case.”On contract lifecycle automation: “It's not just a, you know, search and replace or search and find or go find all these things, but helping understand, you know, what is the best way to rephrase this.”On disaster recovery readiness: “We're basically checking all these systems 24-7 to understand, do we have something brewing out there? I mean, hopefully we don't have a disaster, but we want to be prepared just in case we do.”Recent Book Recommendation: The Boys in the Boat by Daniel James Brown--Like what you hear? Leave us a review and subscribe to the show on Apple, Google, Spotify, Stitcher, or wherever you listen to podcasts.Enterprise AI Innovators is a show where top technology executives share how AI is transforming the enterprise. Each episode covers the real-world applications of AI, from improving products and optimizing operations to redefining the customer experience. Find more great insights from technology leaders and enterprise software experts at https://www.enterprisesoftware.blog/ Enterprise AI Innovators is produced by Josh Meer

De accountancysector kraakt onder de veranderende eisen van het vak. De personeelstekorten zijn groot, wet- en regelgeving verandert en de werkdruk is vaak torenhoog. Maar er zijn ook kansen, zoals de toenemende rol van AI. Wolters Kluwer, een van de vier grote automatiseerders in de branche, wil juist op dit gebied koploper worden. Maar hoe kun je goede software aan je klanten aanbieden als de overheid liever niet wil digitaliseren? Bas Kniphorst, Algemeen Directeur Tax and Accounting Europa bij Wolters Kluwer is te gast in BNR Zakendoen. Macro met Boot Elke dag een intrigerende gedachtewisseling over de stand van de macro-economie. Op maandag en vrijdag gaat presentator Thomas van Zijl in gesprek met econoom Arnoud Boot, de rest van de week praat Van Zijl met econoom Edin Mujagić. Ook altijd terug te vinden als je een aflevering gemist hebt. Blik op de wereld Wat speelt zich vandaag af op het wereldtoneel? Het laatste nieuws uit bijvoorbeeld Oekraïne, het Midden-Oosten, de Verenigde Staten of Brussel hoor je iedere werkdag om 12.10 van onze vaste experts en eigen redacteuren en verslaggevers. Ook los te vinden als podcast. Ondernemerspanel Jumbo stopt met inkoopgigant Everest. Is dit een slimme strategische stap of een risico voor ondernemers? En: Meer diversiteit op de werkvloer leidt lang niet altijd tot meer inclusie. Dat en meer bespreken we om 11.30 in het ondernemerspanel met: Monique Ansink, eigenaar van Jumbo spanbandfabrikant en All day Nuts en Eduard Schaepman, serie-ondernemer Luister l Ondernemerspanel Zakenlunch Elke dag, tijdens de lunch, geniet je mee van het laatste zakelijke nieuws, actuele informatie over de financiële markten en ander economische actualiteiten. Op een ontspannen manier word je als luisteraar bijgepraat over alles wat er speelt in de wereld van het bedrijfsleven en de beurs. En altijd terug te vinden als podcast, mocht je de lunch gemist hebben. Pitch Elke vrijdag is het weer tijd voor jonge ondernemingen om zichzelf op de kaart te zetten. Dat doen zij via een pitch en het doorstaan van een vragenvuur. Vandaag is het de beurt aan: Paul Snijder van LAWA en Casper Smit van The Digital Clinic. Cilian Jansen van Karmijn Kapitaal zal de startups beoordelen en van advies voorzien. Deze jonge ondernemers zijn ook terug te luisteren als podcast. Contact & Abonneren BNR Zakendoen zendt elke werkdag live uit van 11:00 tot 13:30 uur. Je kunt de redactie bereiken via e-mail. Abonneren op de podcast van BNR Zakendoen kan via bnr.nl/zakendoen, of via Apple Podcast en Spotify. See omnystudio.com/listener for privacy information.

De accountancysector kraakt onder de veranderende eisen van het vak. De personeelstekorten zijn groot, wet- en regelgeving verandert en de werkdruk is vaak torenhoog. Maar er zijn ook kansen, zoals de toenemende rol van AI. Wolters Kluwer, een van de vier grote automatiseerders in de branche, wil juist op dit gebied koploper worden. Maar hoe kun je goede software aan je klanten aanbieden als de overheid liever niet wil digitaliseren? In ‘De top van Nederland’ heeft presentator Thomas van Zijl een uitgebreid gesprek met Bas Kniphorst, algemeen directeur Tax and Accounting Europa bij Wolters Kluwer. Over Wolters Kluwer Wolters Kluwer is een toonaangevende softwareaanbieder en uitgever van wetenschappelijke- en vakliteratuur. Het bedrijf bestaat uit vijf takken, gezondheidszorg, fiscaal en accountancy, bedrijfsprestaties en ESG, financiële en zakelijke compliance en juridisch en regelgeving. Over Thomas van Zijl Thomas van Zijl is financieel journalist en presentator bij BNR. Hij presenteert dagelijks ‘BNR Zakendoen’, het Nederlandse radioprogramma voor economisch nieuws en zakelijk inzicht, waar 'De top van Nederland’ onderdeel van is. Ook is hij een van de makers van de podcast ‘Onder curatoren’. Abonneer je op de podcast Ga naar ‘De top van Nederland’ en abonneer je op de podcast, ook te beluisteren via Apple Podcast en Spotify. See omnystudio.com/listener for privacy information.

The team had a wonderful evening at the Accounting Excellence Awards (AEA) and we hope everyone who joined did too! They share their highlights, with Richard Hattersley reflecting on how the winners shed light on trends shaping the profession. Focusing on the small, mid-tier and large firm winners, Hattersley talks about private equity, management buyouts and growth. Many of these winners will also be speaking at the Finance, Accounting and Bookkeeping Show at the NEC, Birmingham, on 11-12 March 2026. Tom Herbert spent the day after the awards at Wolters Kluwer's CCH Connections User Conference. Herbert shares his experience with Wolters Kluwer's integrated Making Tax Digital (MTD) solution ahead of the mandation date, what the next six months are going to look like for firms and the mood among attendees as MTD nears. Matthew Ord concludes the podcast by recalling his chat with ICAEW president, Derek Blair. Appointed in June 2025, Blair outlines the legacy he wants to leave, what his goals are and his focus on a social mobility programme to tap into new talent.

Send us a textKen Crutchfield works with Wolters Kluwer, where he focuses on legal research products that help professionals find and understand laws and regulations. He has spent more than four decades in and around the legal, tax, and accounting industries. Over the years, he has held senior roles at Bloomberg Tax Technology, Thomson Reuters, and LexisNexis. He began his career listening to lawyer support calls in the early days of legal research services and went on to bridge the gap between technical teams and the business side of legal and tax solutions. In this conversation, Ken shares how technology has transformed the legal profession, from early word processing machines to today's AI tools. He also talks about the challenges of access to justice, the importance of balancing legal risk with practical advice, and how lawyers can adapt to new ways of working. Tune in to hear how decades of experience in legal technology shape Ken's views on the future of law, and learn why he believes AI will bring new opportunities for lawyers to deliver better and more efficient service to their clients.Wolters Kluwerhttps://www.wolterskluwer.com Ken Crutchfield https://www.kencrutchfield.com/ Louis Goodman www.louisgoodman.comhttps://www.lovethylawyer.com/510.582.9090Music: Joel Katz, Seaside Recording, MauiTech: Bryan Matheson, Skyline Studios, OaklandAudiograms: Paul Robert louis@lovethylawyer.com

This week, we talk with Gabe Pereyra, President and co-founder at Harvey, about his path from DeepMind and Google Brain to launching Harvey with Winston Weinberg; how a roommate's real-world legal workflows met early GPT-4 access and OpenAI backing; why legal emerged as the right domain for large models; and how personal ties to the profession plus a desire to tackle big societal problems shaped a mission to apply advanced AI where language and law intersect.Gabe's core thesis lands hard, “the models are the product.” Rather than narrow tools for single tasks, Harvey opted for a broad assistant approach. Lawyers live in text and email, so dialog becomes the control surface, an “AI associate” supporting partners and teams. Early demos showed useful output across many tasks, which reinforced a generalist design, then productized connections into Outlook and Word, plus a no-code Workflow Builder.Go-to-market strategy flipped the usual script. Instead of starting small, Harvey partnered early with Allen & Overy and leaders like David Wakeling. Large firms supplied layered review, which reduced risk from model errors and increased learning velocity. From there the build list grew, security and data privacy, dedicated capacity, links to firm systems, case law, DMS, data rooms, and eDiscovery. A matter workspace sits at the center. Adoption rises with surface area, with daily activity approaching seventy percent where four or more product surfaces see regular use. ROI work now includes analysis of write-offs and specialized workflows co-built with firms and clients, for example Orrick, A&O, and PwC.Talent, training, and experience value come next. Firms worry about job paths, and Gabe does not duck that concern. Models handle complex work, which raises anxiety, yet also shortens learning curves. Harvey collaborates on curricula using past deals, plus partnerships with law schools. Return on experience shows up in recruiting, PwC reports stronger appeal among early-career talent, and quality-of-life gains matter. On litigation use cases, chronology builders require firm expertise and guardrails, with evaluation methods that mirror how senior associates review junior output. Frequent use builds a mental model for where errors tend to appear.Partnerships round out the strategy. Research content from LexisNexis and Wolters Kluwer, work product in iManage and NetDocuments, CLM workflows via Ironclad, with plans for data rooms, eDiscovery, and billing. Vision extends to a complete matter management service, emails, documents, prior work, evaluation, billing links, and strict ethical walls, all organized by client-matter. Global requirements drive multi-region storage and controls, including Australia's residency rules. The forward look centers on differentiation through customization, firms encode expertise into models, workflows, and agents, then deliver outcomes faster and at software margins. “The value sits in your people,” Gabe says, and firms that convert know-how into systems will lead the pack.Listen on mobile platforms:  ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Apple Podcasts⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ |  ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Spotify⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ | ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠YouTube⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠[Special Thanks to ⁠Legal Technology Hub⁠ for their sponsoring this episode.] ⁠⁠⁠Email: geekinreviewpodcast@gmail.comMusic: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Jerry David DeCicca⁠⁠⁠⁠⁠⁠⁠⁠⁠ Transcript

In der 63. Folge unseres Podcasts „How to Legal Tech“ freuen wir uns sehr, Dr. Tobias Brors, Partner bei der Arbeitsrechtskanzlei Pusch Wahlig Workplace Law (PWWL), als Gast begrüßen zu dürfen. Tobias ist seit vielen Jahren im Arbeitsrecht tätig und hat sich intensiv mit Legal Tech auseinandergesetzt. Gemeinsam mit unserem Host Luis Stade spricht er über die Frage: Was können Chatbots, AI & Co. im Arbeitsrecht eigentlich leisten?Zu Beginn berichtet Tobias über den Weg von PWWL hin zu Legal Tech: Von den frühen Anfängen mit einer eigenen Entwickler-GmbH bis hin zur heutigen Integration digitaler Lösungen in die arbeitsrechtliche Beratung. Er betont, dass Legal Tech auch ein Lernprozess ist – manches Projekt scheitert, legt aber gleichzeitig die Basis für erfolgreichere Anwendungen. Besonders spannend findet er dabei die Zusammenarbeit mit Softwareentwicklern und Mathematikern, die die anwaltliche Perspektive bereichern.Im Gespräch geht es zudem um konkrete Projekte: angefangen bei einem Chatbot, der Betriebsvereinbarungen für Fachabteilungen zugänglich machte, bis hin zu Tools, die Unternehmen bei Abfindungsverhandlungen unterstützen können. Deutlich wird Tobias' Einstellung zu dem Thema: Erfolgreiche Legal-Tech-Produkte entstehen dort, wo sie ein echtes wirtschaftliches Problem lösen und für Mandanten leicht nutzbar sind.Natürlich darf auch das Thema AI im Arbeitsrecht nicht fehlen. Tobias schildert, wie KI-gestützte Textgenerierung inzwischen - von manchen mehr, von manchen weniger - in der täglichen Arbeit genutzt wird und welche Herausforderungen entstehen, wenn Mandanten ihre Fragen mit „ChatGPT hat gesagt, dass …“ einleiten. Klar ist aber für Tobias und vor allem auch für die Beratung in arbeitsrechtlichen Angelegenheiten: AI verändert den Markt – und Kanzleien müssen darauf Antworten finden.Zu welchen anderen spannenden Thema Tobias und Luis sich ausgetauscht haben und wie genau die Entwicklung von Legal Tech-Tools bei PWWL funktioniert, erfahrt ihr in der 63. Folge von How to Legal Tech. Viel Spaß beim Reinhören und ein großes Dankeschön an Wolters Kluwer, die die Umsetzung unserer Podcasts möglich machen.

In this podcast episode, Dawn Tiura interviews Candiss Kumar, an associate director of strategic sourcing for Wolters Kluwer. Candiss gives a sneak peek into her upcoming Summit session, Building Trust Through Data: The Strategic Sourcing Leader's Guide to Credibility and Compelling Narratives. Candiss shares her insights on the importance of understanding one's business, the role of storytelling in data presentation, and the necessity of curiosity and problem-solving in procurement. The conversation emphasizes the need for sourcing professionals to engage with stakeholders effectively and to present data in a compelling way that drives innovation and decision-making.

Nu lid worden van DeAandeelhouder Pro? Ga naar:https://www.deaandeelhouder.nl/login/?redirect_to=https://www.deaandeelhouder.nl/mijn-account/pro/Meer weten over de mogelijkheden bij Saxo Bank? Klik dan op deze link: https://www.home.saxo/nl-nl/campaigns/invest-for-less?cmpid=disp_cm_31945878_394457563_214280992&dclid=CNe1rrqHyokDFcbsEQgdtWcPJgLid worden van ProBeleggen? Ga naar: https://www.probeleggen.nl/aanmelden/registreren/  Lid worden van de aandeelhouder? Ga naar: https://www.deaandeelhouder.nl/premium/CEO Talk Tom van Aken (Avantium): https://www.youtube.com/watch?v=_p-RIiPhQ0M13 vragen aan CEO Tom van Aken (Avantium): https://www.deaandeelhouder.nl/columns/dertien-vragen-aan-tom-van-aken-ceo-avantium/Alles over de claimemissie Avantium: https://www.deaandeelhouder.nl/columns/claimemissie-avantium-van-start/In de wekelijkse podcast van DeAandeelhouder ontvangt deze week Nico Inberg diverse experts uit de financiële wereld om te praten over de beurs, beleggen en aandelen. Deze week verwelkomen wij Edwin Wierda van Ambassador Vermogensbeheer. Onderwerpen die aan bod komen zijn Nvidia, Intel, ASML, Wolters Kluwer, Avantium, Renteverlaging & veel meer!Volg DeAandeelhouder op andere kanalen:Website: https://www.deaandeelhouder.nl/Twitter (X):  https://twitter.com/deaandeelhouderTikTok:  https://www.tiktok.com/@deaandeelhouderInstagram:  https://www.instagram.com/deaandeelhouder/Facebook: https://www.facebook.com/DeAandeelHouder/LinkedIn: https://www.linkedin.com/company/de-aandeelhouder-nl/Tijdslijn:00:00 - 7:03 Verbazing van de week7:03 - 11:18 Ambassador Vermogensbeheer11:18 - 15:00 Fed & Rente15:00 - 19:25 Intel & Nvidia19:25 - 24:40 Prinsjesdag24:40 - 28:05 Avantium28:05 - 32:25 ASMI32:25 - 36:00 Fugro36:00 - 38:30 DSM-Firmenich 38:30 - 41:20 Wolters Kluwer41:20 - 44:00 PostNL44:00 - 49:30 Thyssenkrupp & Rheinmetall49:30 - 51:10 Tesla51:10 Slotwoorden

This week we sit down with Suzanne Konstance, Vice-President and General Manager for Legal and Regulatory US at Wolters Kluwer. She outlines how the company supports professionals in highly regulated fields with software and authoritative content. Operations span multiple countries with a deliberately local approach, where teams design solutions for each market. Listeners get a clear view of scope, from enterprise legal management to recent additions such as Brightflag, alongside deep subject expertise.Konstance explains a core focus on regulatory compliance across securities, tax, IP, and employment. The aim is simple, help clients stay out of court. Continuous change drives editorial work, with authors and editors tracking shifts, executive orders, and practical effects. Provenance, version history, and context matter, supported by structured meta tagging which helps search and AI retrieve the right source every time.In a segment on trust, the conversation moves to standards for accuracy and auditability. Clients tell Wolters Kluwer quality outranks speed for research, so the team emphasizes authoritative sources and transparent sourcing. Konstance walks through a recent non-exclusive content license with Harvey for primary law from US and German collections, part of a broader collaboration strategy which also includes VitalLaw AI and new cross-border features. The goal is a reliable workflow where answers cite sources, show currency, and fit real practice.Real user labs reinforce these priorities. At AALL, librarians worked hands-on in a sandbox session with no guided prompts, pushing tools to limits and asking tough questions. One theme dominated, transparency, with live citations and source trails visible during use. Editors remain in the loop to curate likely questions, collect feedback, and refine outputs, while openness about progress helps teams separate market sizzle from dependable results.Looking ahead, Konstance expects roles to shift toward managing agents and setting clear instructions, similar to supervising a room full of interns, with strong expertise still required for oversight. Teams will need to train newcomers on fundamentals, auditing, and controls, so technology serves professionals, not the reverse. She also shares sources she follows, industry conversations with customers, conferences, LinkedIn, X, plus guidance from a long-standing internal Center of Excellence for AI. For more on Wolters Kluwer initiatives, listeners can visit wolterskluwer.com and explore the Legal and Regulatory section along with the AI hub.Also, check out Jerry David DeCicca and his new album, Cardiac Country.Links:Wolters Kluwer Legal & Regulatory U.S. page Wolters Kluwer's AI centerThe press release announcing the content licensing agreement with HarveyVitalLawListen on mobile platforms:  ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Apple Podcasts⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ |  ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Spotify⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ | ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠YouTube⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠[Special Thanks to ⁠Legal Technology Hub⁠ for their sponsoring this episode.] Blue Sky: ⁠⁠@geeklawblog.com⁠⁠ ⁠⁠@marlgeb⁠⁠⁠⁠⁠⁠⁠Email: geekinreviewpodcast@gmail.comMusic: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Jerry David DeCicca⁠⁠⁠⁠⁠⁠⁠⁠⁠Transcript:

Der Aktien-Schnelltest mit Michael Hüsgen ("BerneckerTV") und Oliver Kantimm ("Der Aktionärsbrief"). Hier im Beitrag gibt es die Podcast-Variante zur eigentlichen Sendung im Rahmen von BerneckerTV, Aufzeichnung am 07.08.2025). Schlaglichter:Wolters Kluwer - Ist der Boden erreicht?Werblicher Hinweis auf Anlegertag und Messe-AngeboteBuzzi Unicem - US-Infrastruktur als Wachstumstreiber im BlickKlarna - Buy now, pay later: Risiko oder Chance?Frosta - Langfristig hochsolide, konservativer Kauf?=======Lust auf noch mehr Sendungen im Bernecker.TV? Noch mehr unterschiedliche Experten? Infos zu Bernecker.TV:https://www.bernecker.info/bernecker-tv=======Anmeldung zum kostenlosen Experten-Newsletter der Bernecker-Redaktion über unsere Website:https://www.bernecker.info/newsletter

Dividendenaktien bleiben ein Fundament für langfristigen Vermögensaufbau – doch welche Werte bieten aktuell das größte Potenzial? In dieser Marktanalyse sprechen Richard “Richy” Dittrich (Boerse Stuttgart Group) und Torsten Tiedt (Aktienfinder.net) über die attraktivsten Dividenden-Stars und deren Chancen auf einen Turnaround. Im Fokus stehen PepsiCo, LVMH und Wolters Kluwer. Die Experten beleuchten, wie sich operative Herausforderungen auf die Bewertung auswirken, warum die persönliche Dividendenrendite oft entscheidender ist als die offizielle Kennzahl und welche Rolle Diversifikation im Portfolio spielt. Diese Top 50 Dividenden-Aktien kaufen Deutschlands Aktionäre im Sommer 2025.

Listen in for a masterclass in courage: not the absence of fear, but the refusal to let fear run the show. Mark Friedlich grew up in a tenement apartment on the Lower East Side of Manhattan, the son of Holocaust survivors, sharing a bedroom and living with scarcity. Today, he speaks on global stages, testifies before Congress, and serves as Vice President of Government Affairs at a multinational corporation. He also stutters, sometimes noticeably, always unapologetically. In this raw, powerful conversation, Mark shares how he built a career at the highest levels of leadership without ever hiding his voice. He doesn't minimize his fear. He prepares. He shows up. He speaks anyway. If you've ever feared speaking up in a meeting, on a stage, or in a tough conversation, this episode will change how you see fear, confidence, and what it really means to own your voice. In this episode on how to own your voice in high-stakes situations, you'll discover: Why Mark never saw stuttering as an impediment, and what that mindset unlocked for him; The difference between fear that stops us and fear that sharpens us; How to own your voice in high-stakes situations, even if you stutter; How to respond with strength and grace when other people give you “the look”; How preparation, mindset, and choosing discomfort can be antidotes to holding back; Mark's memorable conversation with President Bill Clinton; And more. AUDIO TIMESTAMPS 00:00 – Introduction to TranscendingX and the Power of Voice 01:17 – Meet Mark Friedlich: From Stuttering and Scarcity to Executive Leadership 04:14 – What It's Like to Be a VP of Government Affairs in a Global Corporation 07:03 – How Preparation Builds Confidence in High-Stakes Situations 17:29 – Redefining Stuttering: From Weakness to Source of Strength 19:51 – Why Authenticity Creates Trust and Lasting Impact 21:02 – Owning Personal Identity and Evolving With Intention 22:33 – How to Handle Social Reactions and Stay Grounded 25:06 – Standing Up for Yourself with Clarity and Respect 25:56 – Understanding the Personal and Professional Cost of Speaking Up 29:00 – Strategic Preparation Tips for Confident Communication 33:51 – Final Reflections on Leadership, Courage, and Being Seen ABOUT THE GUEST Mark Friedlich, ESQ, CPA is Vice President of Government Affairs for a multinational software corporation, advising the Senate Finance Committee, House Ways and Means Committee, and multiple presidential administrations. With senior executive experience at PwC, Thomson Reuters, and Wolters Kluwer, he's recognized as a leading authority on tax, accounting, and economic policy. Mark serves on the IRS Board, AICPA, and HBR Advisory Council. A person who stutters, Mark grew up on New York's Lower East Side with Holocaust survivor parents and transformed potential limitations into leadership strengths. From testifying before Congress to mentoring young professionals who stutter, Mark demonstrates that authentic leadership means owning every part of yourself. Preparation is everything. Authenticity is non-negotiable. Every fear presents an opportunity. QUOTES “Put yourself in uncomfortable situations because that's the only way one will grow” - Mark Friedlich “We can't control most situations. The only thing we are able to control is how we react.” - Mark Friedlich “Whether you think you have a speech impediment or you don't think you have a speech impediment, you're right.” - Uri Schneider ABOUT THE HOST Uri Schneider, M.A. CCC -SLP is co-founder and leader at Schneider Speech; creator and host of Transcending Stuttering; and former faculty at the University of California, Riverside School of Medicine. SEE ALL SHOW NOTES http://www.transcendingx.com/podcast LEARN MORE at http://www.transcendingx.com and http://www.schneiderspeech.com

In this week's episode of Dividend Talk, we kick off with our Q2 performance review , looking at how our dividend portfolios fared, what we bought, sold, and learned over the past quarter.  We also dive into three big names making headlines: Wolters Kluwer's sharp share price drop and the fear of AI disruption, Novo Nordisk's earnings and competition with Eli Lilly, and UnitedHealth's reduced outlook.  Along the way, we cover dividend hikes and cuts from around the globe, have some laughs over corporate slogans, and answer a packed list of listener questions ranging from sector risks to portfolio construction. SEE YOU ON THE INSIDE!! Tickers discussed: WKL.AS, NVO, LLY, UNH, HEIA.AS, NN.AS, AD.AS, ITW, CLX, AWR, WHR, LGEN.L, MRK, LVMH.PA, TGT, LYB, NKE,CVX, HPQ, MSFT, SHEL, BTI, BAM, BAES.L, HORNB.BR, UPS, PEP, CCOI, ORA.PA,ASR.AS, ASML.AS, UL, GLB.IR, KRZ.F, KESKOB.HE, KNEBV.HE, SAMPO.HE, AGE.BR, XIOR.BR,ASC.BR, SHL.DE, DEF.F, NVO-B.CO, VICI, RY, DOL.TO, FTS.TO, UKW.L, VOLVB.ST,INVE-A.ST, INVE-B.ST, SEB-A.ST, SWED-A.ST, HAND-B.ST, SHELL.AS, VIE.PA, O,SECUB.ST, ABBV, BAYN.DE.  Join us :[Facebook]  - Https://www.facebook.com/groups/dividendtalk[Twitter] -   @DividendTalk_    ,  @European_DG[Discord] - https://discord.gg/nJyt9KWAB5[Premium Services] - https://dividendtalk.eu/how-it-works

Today's discussion comes from our 2025 Annual Conference, The Rise of AI and Automation. For the next 5 weeks, we'll feature a series of panel discussions from our conference. Today's episode is part of our second panel, “Does AI Have an Ethics Problem?”, and will be followed by 2 panels on Practical Applications of AI and AI and Inequality.Our panel is led by Dr. Sandeep Sacheti, and was recorded in June of 2025.Dr. Sandeep Sacheti is a recognized leader in data-driven decision making and operational excellence. As a former Executive Vice President at Wolters Kluwer, he successfully led a global team in delivering innovative solutions in regulatory compliance and financial services that significantly improved business performance, customer experience, and employee engagement. His expertise spans a wide range of areas, including data analytics, risk management, and operational transformation, making him a sought-after advisor and mentor. He holds 20+ patents in information management, customer relationship management, and fraud detection. Besides Wolters Kluwer, he has held senior positions at UBS and American Express. He currently serves on the Board of Advisors at Stevens Institute of Technology as Industry Chair, bridging academia and industry, and is a Board Member at the College of Natural Resources, University of California at Berkeley. An award-winning thought leader in AI, business transformation, and AI-enabled compliance solutions, he holds a Ph.D. from UC Berkeley and a Master's from the University of Massachusetts Amherst, fueling his lifelong commitment to innovation and mentorship.Together, we discussed the importance of regulating AI with an ethical lens, the different use applications of AI across society, and why we can't survive without it. To check out more of our content, including our research and policy tools, visit our website: https://www.hgsss.org/

This week, we welcome longtime friend and legal tech veteran Ken Crutchfield, founder of Spring Forward Consulting. Ken brings his extensive experience from major legal information vendors like Thomson Reuters, Bloomberg, and Wolters Kluwer into a timely and candid discussion about the current phase of artificial intelligence in the legal industry. Comparing today's generative AI surge to the American Industrial Revolution, Ken describes this moment as the “Wild West” era—full of promise, hype, overinvestment, and, critically, few rules.Drawing historical parallels to railroads, oil barons, and steel magnates, Ken illustrates how unchecked growth and technological innovation can outpace regulation until market forces or policy catch up. He notes the resurgence of large-scale infrastructure investment, now not in steel or steam, but in compute power and data centers. Just as J.P. Morgan helped stabilize chaotic markets in the 19th century, Ken suggests today's AI frontier needs a similar recalibration, and possibly new rules of engagement.The conversation shifts toward the practical realities of legal tech adoption. Ken emphasizes that law firms' expectations of perfection often collide with startups' resource limitations. Vendors need to rethink how they engage with firms by building credibility, focusing on integration, and delivering actual use-case wins. Firms, in turn, must move beyond the billable hour mindset and consider new metrics like Return on Experience. Adoption is no longer optional, it's strategic, competitive, and increasingly client-driven.Ken also unpacks the looming implications of content rights and data ownership in the age of AI. If firms aren't investing in data hygiene now, they risk being left behind when more sophisticated AI tools demand clean, structured, and secure datasets. AI isn't just about automating workflows, it's about being ready to plug into a future where interoperability, metadata, and permissions will dictate who thrives and who gets leapfrogged.Finally, Ken calls for scenario planning: not just reacting to what OpenAI or Anthropic might do next, but anticipating it. Firms and vendors alike should double down on what works, define success before launching new projects, and invest in meaningful adoption strategies. In a world moving this fast, it's no longer about who gets there first, it's about who gets there with a plan.Listen on mobile platforms:  ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Apple Podcasts⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ |  ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Spotify⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ | ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠YouTube⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠[Special Thanks to ⁠Legal Technology Hub⁠ for their sponsoring this episode.] Blue Sky: ⁠⁠@geeklawblog.com⁠⁠ ⁠⁠@marlgeb⁠⁠⁠⁠⁠⁠⁠Email: geekinreviewpodcast@gmail.comMusic: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Jerry David DeCicca⁠⁠⁠⁠⁠⁠⁠⁠⁠Transcript

Get YDS Merch before July 25!!Support us on Patreon!This week on Your Diet Sucks, we're talking hormones: what they are, what they do, and why they've become the latest scapegoat for every diet culture grift on the internet. From adrenal fatigue (not real) to seed cycling (also not real), Zoë and Kylee cut through the pseudoscience and explain what actually supports hormone health—like eating enough, managing stress, and getting some damn sleep. We also take a look at the unhinged history of hormone manipulation (yes, monkey testicle transplants come up), why cortisol isn't your enemy, and what to do if your hormones actually feel off. If you've ever been told to “balance your hormones” with a supplement stack or juice cleanse, this episode is for you.Thanks to our sponsors:Get over 70 biomarkers analyzed and get personalized nutrition recommendations adn support, tailored specifically for athletes with Eternal's new Foundations membership. Try Tailwind's limited edition blueberry lemonade! Use YOURDIET20 for 20% OFF first order.Check out Janji's new summer shorts, sports bras, packs, and more! Use code YDS10 for 10% off!Run, bike, ski, with Microcosm Coaching. We coach humans, not just athletes. Book a free consultation call today!ReferencesBayliss, W. M., & Starling, E. H. (1902). The mechanism of pancreatic secretion. The Journal of Physiology, 28(5), 325–353. https://doi.org/10.1113/jphysiol.1902.sp000911Cadegiani, F. A., & Kater, C. E. (2016). Adrenal fatigue does not exist: A systematic review. BMC Endocrine Disorders, 16, 48. https://doi.org/10.1186/s12902-016-0128-4Cohen, P. A., Avula, B., Venhuis, B., Travis, J. C., Wang, Y. H., & Khan, I. A. (2014). Pharmaceutical ingredients in botanical dietary supplements: A review of the literature. Drug Testing and Analysis, 6(7–8), 587–596. https://doi.org/10.1002/dta.1525Duggan, C., Carbo, J. M., Wang, C. Y., et al. (2015). Effects of carbohydrate intake on the thyroid axis and reproductive hormones in healthy adults: A randomized controlled feeding study. Nutrition Journal, 14, 70. https://doi.org/10.1186/s12937-015-0054-6Hamilton-Reeves, J. M., Vazquez, G., Duval, S. J., Phipps, W. R., Kurzer, M. S., & Messina, M. J. (2010). Clinical studies show no effects of soy protein or isoflavones on reproductive hormones in men: Results of a meta-analysis. Fertility and Sterility, 94(3), 997–1007. https://doi.org/10.1016/j.fertnstert.2009.04.038Kantor, E. D., Rehm, C. D., Du, M., White, E., & Giovannucci, E. L. (2016). Trends in dietary supplement use among US adults from 1999–2012. JAMA, 316(14), 1464–1474. https://doi.org/10.1001/jama.2016.14403Messina, M. (2010). Insights gained from 20 years of soy research. The Journal of Nutrition, 140(12), 2289S–2295S. https://doi.org/10.3945/jn.110.124107Mountjoy, M., Sundgot-Borgen, J., Burke, L., et al. (2018). International Olympic Committee (IOC) consensus statement on relative energy deficiency in sport (RED-S): 2018 update. British Journal of Sports Medicine, 52(11), 687–697. https://doi.org/10.1136/bjsports-2018-099193Ross, A. C., Caballero, B. H., Cousins, R. J., Tucker, K. L., & Ziegler, T. R. (Eds.). (2020). Modern nutrition in health and disease (12th ed.). Wolters Kluwer.Takamine, J. (1901). The isolation of the active principle of the suprarenal gland. The Journal of the American Medical Association, 36(24), 1698–1698. https://doi.org/10.1001/jama.1901.02470350030010

On today's legally speaking podcast, I'm delighted to be joined by Martin O'Malley. Martin is the CEO of Wolters Kluwer Legal & Regulatory Division. He has more than 20 years of experience in operation, sales, customer support, product development and marketing. Martin has led businesses across Europe, the US, Asia, Pacific, and has extensive international experience.So why should you be listening in? You can hear Rob and Martin discussing:- The Exploration of AI's Transformative Potential and its Importance- Quality and Trust in AI Solutions- Challenges of AI Adoption- Not Just Implementing Technology, But Helping Professionals Change Their Work Processes- The Future of Legal WorkConnect with Martin here - https://nl.linkedin.com/in/martinomalley

Send us a textGenerative AI is transforming the way clinicians interact with technology. In this episode, Dr. Holly Urban, VP of Business Development at Wolters Kluwer, joins John Driscoll to discuss how AI, ambient listening tools, and trusted medical content like UpToDate are improving clinical workflows, easing documentation burdens, and making healthcare delivery more precise, efficient, and human-centered.

Episode 198: Fatigue.  Future doctors Redden and Ibrahim discuss with Dr. Arreaza the different causes of fatigue, including physical and mental illnesses. Dr. Arreaza describes the steps to evaluate fatigue. Some common misconceptions are explained, such as vitamin D deficiency and “chronic Lyme disease”. Written by Michael Ibrahim, MSIV, and Jordan Redden, MSIV, Ross University School of Medicine. Edits and comments by Hector Arreaza, MDYou are listening to Rio Bravo qWeek Podcast, your weekly dose of knowledge brought to you by the Rio Bravo Family Medicine Residency Program from Bakersfield, California, a UCLA-affiliated program sponsored by Clinica Sierra Vista, Let Us Be Your Healthcare Home. This podcast was created for educational purposes only. Visit your primary care provider for additional medical advice.Dr. Arreaza: Today is a great day to talk about fatigue. It is one of the most common and most complex complaints we see in primary care. It involves physical, mental, and emotional health. So today, we're walking through a case, breaking down causes, red flags, and how to work it up without ordering the entire lab catalog.Michael:Case: This is a 34-year-old female who comes in saying, "I've been feeling drained for the past 3 months." She says she's been sleeping 8 hours a night but still wakes up tired. No recent illnesses, no weight loss, fever, or night sweats. She denies depression or anxiety but does report a lot of work stress and taking care of her two little ones at home. She drinks 2 cups of coffee a day, doesn't drink alcohol, and doesn't use drugs. No medications, just a multivitamin. Regular menstrual cycles—but she's noticed they've been heavier recently.Jordan:Fatigue is a persistent sense of exhaustion that isn't relieved by rest. It's different from sleepiness or muscle weakness.Classification based on timeline:    •   Acute fatigue: less than 1 month    •   Subacute: 1 to 6 months    •   Chronic: more than 6 monthsThis patient's case is subacute—going on 3 months now.Dr. Arreaza:And we can think about fatigue in types:    •   Physical fatigue: like muscle tiredness after activity    •   Mental fatigue: trouble concentrating or thinking clearly (physical + mental when you are a medical student or resident)    •    Pathological fatigue: which isn't proportional to effort and doesn't get better with restAnd of course, there's chronic fatigue syndrome, also called myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS), which is a diagnosis of exclusion after 6 months of disabling fatigue with other symptoms.Michael:The differential is massive. So, we can also group it by systems.Jordan:Let's run through the big ones.Endocrine / Metabolic Causes    • Hypothyroidism: A classic cause of fatigue. Often associated with cold intolerance, weight gain, dry skin, and constipation. May be subtle and underdiagnosed, especially in women.    • Diabetes Mellitus: Both hyperglycemia and hypoglycemia can cause fatigue. Look for polyuria, polydipsia, weight loss, or blurry vision in undiagnosed diabetes.    • Adrenal Insufficiency: Think of this when fatigue is paired with hypotension, weight loss, salt craving, or hyperpigmentation. Can be primary (Addison's) or secondary (e.g., due to long-term steroid use).Michael: Hematologic Causes    • Anemia (especially iron deficiency): Very common, especially in menstruating women. Look for fatigue with pallor, shortness of breath on exertion, and sometimes pica (craving non-food items).     • Vitamin B12 or Folate Deficiency: B12 deficiency may present with fatigue plus neurologic symptoms like numbness, tingling, or gait issues. Folate deficiency tends to present with megaloblastic anemia and fatigue.    • Anemia of Chronic Disease: Seen in patients with chronic inflammatory conditions like RA, infections, or CKD. Typically mild, normocytic, and improves when the underlying disease is treated.Michael: Psychiatric Causes    • Depression: A major driver of fatigue, often underreported. May include anhedonia, sleep disturbance, appetite changes, or guilt. Sometimes presents with only somatic complaints.    • Anxiety Disorders: Mental fatigue, poor sleep quality, and hypervigilance can leave patients feeling constantly drained.    • Burnout Syndrome: Especially common in caregivers, healthcare workers, and educators. Emotional exhaustion, depersonalization, and reduced personal accomplishment are key features.Jordan: Infectious Causes    • Epstein-Barr Virus (EBV):Mononucleosis is a well-known cause of fatigue, sometimes lasting weeks. May also have sore throat, lymphadenopathy, and splenomegaly.    • HIV:Consider it in high-risk individuals. Fatigue can be an early sign, along with weight loss, recurrent infections, or night sweats.    • Hepatitis (B or C):Can present with chronic fatigue, especially if liver enzymes are elevated. Screen at-risk individuals.    • Post-viral Syndromes / Long COVID:Fatigue that lingers for weeks or months after viral infection. Often, it includes brain fog, muscle aches, and post-exertional malaise.Important: Chronic Lyme disease is a controversial term without a consistent clinical definition and is often used to describe patients with persistent, nonspecific symptoms not supported by objective evidence of Lyme infection. Leading medical organizations reject the term and instead recognize "post-treatment Lyme disease syndrome" (PTLDS) for persistent symptoms following confirmed, treated Lyme disease, emphasizing that prolonged antibiotic therapy is not effective. Research shows no benefit—and potential harm—from extended antibiotic use, and patients with unexplained chronic symptoms should be thoroughly evaluated for other possible diagnoses.Michael: Cardiopulmonary Causes    •   Congestive Heart Failure (CHF): Fatigue from poor perfusion and low cardiac output. Often comes with dyspnea on exertion, edema, and orthopnea.    •   Chronic Obstructive Pulmonary Disease (COPD): Look for a smoking history, chronic cough, and fatigue from hypoxia or the work of breathing.    •   Obstructive Sleep Apnea (OSA): Daytime fatigue despite adequate hours of sleep. Patients may snore, gasp, or report morning headaches. High suspicion in obese or hypertensive patients.Jordan:Autoimmune / Inflammatory Causes    •   Systemic Lupus Erythematosus (SLE): Fatigue is often an early symptom. May also see rash, arthritis, photosensitivity, or renal involvement.    •   Rheumatoid Arthritis (RA): Fatigue from systemic inflammation. Morning stiffness, joint pain, and elevated inflammatory markers point to RA.    •   Fibromyalgia: A chronic pain syndrome with widespread tenderness, fatigue, nonrestorative sleep, and sometimes cognitive complaints ("fibro fog").Cancer / Malignancy    •   Leukemia, lymphoma, or solid tumors: Fatigue can be the first symptom, often accompanied by weight loss, night sweats, or unexplained fevers. Consider when no other cause is evident.Michael:Medications:Common culprits include:    ◦   Beta-blockers: Can slow heart rate too much.    ◦   Antihistamines: Sedating H1 blockers like diphenhydramine.    ◦   Sedatives or sleep aids: Can cause grogginess and daytime sedation.    •   Substance Withdrawal: Fatigue can be seen in withdrawal from alcohol, opioids, or stimulants. Caffeine withdrawal, though mild, can also contribute.Dr. Arreaza:Whenever we evaluate fatigue, we need to keep an eye out for red flags. These should raise suspicion for something more serious:    •   Unintentional weight loss    •   Night sweats    •   Persistent fever    •   Neurologic symptoms    •   Lymphadenopathy    •   Jaundice    •   Palpitations or chest painThis patient doesn't have these—but that doesn't mean we stop here.Dr. Arreaza:Those are a lot of causes, we can evaluate fatigue following 7 steps:Characterize the fatigue.Look for organic illness.Evaluate medications and substances.Perform psychiatric screening.Ask questions about quantity and quality of sleep.Physical examination.Undertake investigations.So, students, do we send the whole lab panel?Michael:Not necessarily. Labs should be guided by history and physical. But here's a good initial panel:    •   CBC: To check for anemia or infection    • TSH: Screen for hypothyroidism    • CMP: Look at electrolytes, kidney, and liver function    • Ferritin and iron studies    • B12, folate    • ESR/CRP for inflammation (not specific)    • HbA1c if diabetes is on the radarJordan:And if needed, consider:    • HIV, EBV, hepatitis panel    • ANA, RF    • Cortisol or ACTH stimulation testImaging? Now that's rare—unless there are specific signs. Like chest X-ray for possible cancer or TB, or sleep study if you suspect OSA.Dr. Arreaza:Unaddressed fatigue isn't just inconvenient. It can impact on quality of life, affect job performance, lead to mood disorders, delay diagnosis of serious illness, increase risk of accidents—especially driving. So, don't ignore your patients with fatigue!Jordan:And some people—like women, caregivers, or shift workers—are especially at risk.Michael:The cornerstone of treatment is addressing the underlying cause.Jordan:If it's iron-deficiency anemia—treat it. If it's depression—get mental health involved. But there's also: Lifestyle Support: Better sleep hygiene, light physical activity, mindfulness or CBT for stress, balanced nutrition—especially iron and protein, limit caffeine and alcoholDr. Arreaza:Sometimes medications help—but rarely. And for chronic fatigue syndrome, the current best strategies are graded exercise therapy and CBT, along with managing specific symptoms. Beta-alanine has potential to modestly improve muscular endurance and reduce fatigue in older adults, but more high-quality research is needed.SSRI: fluoxetine and sertraline. Iron supplements: Even without anemia, but low ferritin [Anecdote about low ferritin patient]Jordan:This case reminds us to take fatigue seriously. In her case, it may be multifactorial—work stress, caregiving burden, and possibly iron-deficiency anemia. So, how would we wrap up this conversation, Michael?Michael:We don't need to order everything under the sun. A focused history and exam, targeted labs, and being alert to red flags can guide us.Jordan:And don't forget the basics—sleep, stress, and nutrition. These are just as powerful as any prescription.Dr. Arreaza:We hope today's episode on fatigue has given you a clear framework and some practical tips. If you enjoyed this episode, share it and subscribe for more evidence-based medicine!Jordan:Take care—and get some rest~___________________________Even without trying, every night you go to bed a little wiser. Thanks for listening to Rio Bravo qWeek Podcast. We want to hear from you, send us an email at RioBravoqWeek@clinicasierravista.org, or visit our website riobravofmrp.org/qweek. See you next week! _____________________References:DynaMed. (2023). Fatigue in adults. EBSCO Information Services. https://www.dynamed.com (Access requires subscription)Jason, L. A., Sunnquist, M., Brown, A., Newton, J. L., Strand, E. B., & Vernon, S. D. (2015). Chronic fatigue syndrome versus systemic exertion intolerance disease. Fatigue: Biomedicine, Health & Behavior, 3(3), 127–141. https://doi.org/10.1080/21641846.2015.1051291Kroenke, K., & Mangelsdorff, A. D. (1989). Common symptoms in ambulatory care: Incidence, evaluation, therapy, and outcome. The American Journal of Medicine, 86(3), 262–266. https://doi.org/10.1016/0002-9343(89)90293-3National Institute for Health and Care Excellence. (2021). Myalgic encephalomyelitis (or encephalopathy)/chronic fatigue syndrome: Diagnosis and management (NICE Guideline No. NG206). https://www.nice.org.uk/guidance/ng206UpToDate. (n.d.). Approach to the adult patient with fatigue. Wolters Kluwer. https://www.uptodate.com (Access requires subscription)Theme song, Works All The Time by Dominik Schwarzer, YouTube ID: CUBDNERZU8HXUHBS, purchased from https://www.premiumbeat.com/.

Episode Summary What if brand wasn't a guideline or a campaign—but an operating system?Eric Alberts is helping reinvent a 190-year-old company by treating brand like a product—complete with documentation, demos, and internal adoption strategies. As Design Director at Wolters Kluwer, he's drawing on a decade of UX and product design experience to build scalable systems that make brand feel more like infrastructure than identity theater.In this episode, Eric shares how he's operationalizing brand across a decentralized, 22,000-person org—creating internal education programs, vetting agency partnerships, and empowering teams with self-service tools.We talk brand architecture, creative ops as connective tissue, and how to evolve brand from aesthetics to an engine for business alignment.Key TakeawaysBrand is more than visual identity—it's infrastructure for business and storytelling.Creative ops becomes powerful when it connects internal teams and external partners.Documentation, measurement, and system design aren't just for product teams—they're essential for scaling brand.The in-house team can be a Trojan horse for embedding brand strategy—starting with service, growing into influence.AI won't replace creativity, but it can supercharge consistency, scale, and speed—if the system is sound.Passive Listening to Active Thinking Use these prompts to reflect solo—or spark deep conversations with your team:Are you building brand like a story—or like a system?What would change if your in-house team treated brand like a product with documentation, adoption, and iteration?If your brand were a product, how would you measure adoption?What's stopping your external agencies from becoming true extensions of your internal brand system?Where is creative ops acting like connective tissue—and where is it still a service desk?

Episode 194: Acute low back pain.  Future Dr. Ibrahim presents a clinical case to explain the essential points in the evaluation of back pain.  Future Dr. Redden adds information about differentiating between a back strain and more serious diseases such as cancer, and Dr. Arreaza shares information about returning to work after back strain.Written by Michael Ibrahim, MSIV. Editing and comments by Jordan Redden, MSIV, and Hector Arreaza, MD.You are listening to Rio Bravo qWeek Podcast, your weekly dose of knowledge brought to you by the Rio Bravo Family Medicine Residency Program from Bakersfield, California, a UCLA-affiliated program sponsored by Clinica Sierra Vista, Let Us Be Your Healthcare Home. This podcast was created for educational purposes only. Visit your primary care provider for additional medical advice.Dr. Arreaza:Welcome back, everyone. Today's topic is one that every primary care provider, emergency doctor, and even specialist sees routinely: low back pain. It's so common that studies estimate up to 80% of adults will experience it at some point in their lives. But despite how frequent it is, the challenge is to identify which cases are benign and which demand urgent attention.Jordan:Exactly. Low back pain is usually self-limiting and mechanical in nature, but we always need to keep an eye out for the rare but serious causes: things like infection, malignancy, or neurological compromise. That's why a good history and physical exam are our best tools right out of the gate.Michael:And to ground this in a real example, let me introduce a patient we saw recently. John is a 45-year-old warehouse worker who came in with two weeks of lower back pain that started after lifting a 50-lb box. He describes it as a dull, aching pain that radiates from his lower back down the posterior left thigh into the calf. He says it gets worse with bending or coughing, but he feels better when lying flat. He also mentioned some numbness in his left foot, but he denies any bowel or bladder issues. His vitals are completely normal. On exam, he had lumbar paraspinal tenderness, a positive straight leg-raise at 40 degrees on the left and decreased sensation in the L5 dermatome, though reflexes were still intact.Dr. Arreaza:That's a great case. Let's take a minute and talk about the straight leg raise test. This is a bedside tool we use to assess for lumbar nerve root irritation often caused by a herniated disc. ***Here's how it works: the patient lies supine, and you slowly raise their straight leg. If pain radiates below the knee between 30° and 70°, that suggests radiculopathy, especially involving the L5 or S1 nerve roots. Pain at higher angles is more likely due to hamstring tightness or mechanical strain.Michael:Right. So, stepping back: what do we mean by "low back pain"? Broadly, it's any pain localized to the lumbar spine, but it's often classified by type or cause:Mechanical (like muscle strain or degenerative disc disease), Radicular (nerve root involvement), Referred pain (like from pelvic or abdominal organs), Inflammatory (AS), and Systemic or serious causes like infection or malignancy. Jordan:In John's case, we're thinking radicular pain, most likely from a herniated disc compressing the L5 nerve root. That's supported by the dermatomal numbness, the leg pain, and that positive straight leg test.Dr. Arreaza:Good reasoning. Now, anytime we see back pain, our brains should run a checklist for red flags. These help us pick up more serious causes that require urgent attention. Let's run through the red flags.Michael:Sure. For fracture, we think about major trauma or even minor trauma in the elderly, especially those with osteoporosis or on chronic steroids. Also, anyone over 70 years old.Jordan:Then we have infections, which could include things like discitis, vertebral osteomyelitis, or epidural abscess. Red flags include fever, IV drug use, recent surgery, or immunosuppression.Michael:Malignancy is another critical one, especially if there's a history of breast, prostate, lung, kidney, or thyroid cancer. Clues include unexplained weight loss, night pain, or constant pain not relieved by rest.Jordan:And don't forget about inflammatory back pain, like ankylosing spondylitis, which is often seen in younger patients with morning stiffness that lasts more than 30 minutes and improves with activity.Dr. Arreaza:And of course, we always rule out cauda equina syndrome: a surgical emergency. That's urinary retention or incontinence, saddle anesthesia, bilateral leg weakness, or fecal incontinence. Missing this diagnosis can be catastrophic.Michael:Thankfully, in John's case, we don't see any red flags. His presentation is classic for uncomplicated lumbar radiculopathy. But we must stay vigilant, because sometimes patients don't offer up key symptoms unless we ask directly.Jordan:And that's where associated symptoms help guide us. For example:Radicular symptoms like numbness or weakness follow dermatomal patterns. Constitutional symptoms like fever or weight loss raise red flags. Bladder/bowel changes or saddle anesthesia raise alarms for cauda equina. Pain that wakes patients up at night might point to malignancy. Dr. Arreaza:So when do we order labs or imaging?Michael:Not right away. For most patients with acute low back pain, imaging is not needed unless they have red flags. If infection is suspected, we'd get CBC, ESR, and CRP. For cancer, maybe PSA or serum protein electrophoresis. And if inflammatory back disease is suspected, HLA-B27 can be helpful.Jordan:Yes, imaging should be delayed for at least six weeks unless red flags or significant neurologic deficits are present. When we do image, MRI is our go-to especially for suspected radiculopathy or cauda equina. X-rays can help if we're thinking about fractures, but they won't show soft tissue or nerve root issues.Michael:In the example from our case, since the patient doesn't have red flags, we'd go with conservative management: start NSAIDs and recommend activity modification. As this is the acute setting, physical therapy would not be recommended.Jordan:For the acute phase, research shows no serious difference between those with PT and those without in the long term. However, physical therapy is really the cornerstone of management for chronic back pain. It's not just movement: it's education, body mechanics, and teaching patients how to move safely. And PT can actually reduce opioid use, imaging, and injections down the line for patient struggling with long term back pain.Dr. Arreaza:Yes, and PT is not one-size-fits-all. PT might include McKenzie exercises, manual therapy, postural retraining, or even neuromuscular re-education. The goal is always to build core stability, promote healthy movement patterns, and reduce fear of motion.Jordan:Let's take a minute to talk about the McKenzie Method, a physical therapy approach used to treat lumbar disc herniation by identifying a specific movement, (often spinal extension) that reduces or centralizes pain. A common exercise is the prone press-up, (cobra pose for yoga fans) where the patient lies face down and pushes the upper body upward while keeping the hips on the floor to relieve pressure on the disc. These exercises should be done carefully, ideally under professional guidance, and discontinued if symptoms worsen.Michael:For our case patient, our working diagnosis is mechanical low back pain with L5 radiculopathy. No imaging needed now, no red flags. We'll treat conservatively and educate him about proper lifting, staying active, and recovery expectations.Jordan:We also emphasized to him that bed rest isn't helpful. In fact, bed rest can make things worse. Keeping active while avoiding heavy lifting for now is key.Dr. Arreaza:Return-to-work recommendations should be individualized. For example, an office worker, positioning while working, or work hours may be able to return to work promptly. However, those with physically demanding jobs may need light duty or be off work.Ice: no evidence of benefit. Heat: may reduce pain and disability in pain of less than 3 months, although the benefit was small and short.And we should always teach safe lifting techniques: bend at the knees, keep the load close, avoid twisting. It's basic knowledge, but it is very effective in preventing recurrence.Jordan:Now, if a patient fails to improve after 6 weeks of conservative therapy, or if they develop new neurologic deficits, that's when we think about referral to spine specialists or surgical consultation.Michael:And as previously mentioned: in cases where back pain becomes chronic (lasting more than 12 weeks) a multidisciplinary approach works best. That can include:Physical therapy, Cognitive behavioral therapy (CBT) And sometimes pain management interventions. Jordan:We can't forget the psychological toll either. Chronic back pain is associated with depression, anxiety, and opioid dependence. Increased risk factors include obesity, smoking, sedentary lifestyle, and previous back injuries.Dr. Arreaza:Well said. So, let's summarize. Michael?Michael:Sure! Low back pain is common, and most cases are benign. But we have to know the red flags that point to serious pathology. A focused history and physical exam are more powerful than many people realize. And the first step in treatment is almost always conservative, with a strong emphasis on maintaining physical activity.Jordan:And don't underestimate the value of patient education. Helping patients understand their pain, set realistic expectations, and stay active is often just as important as the medications or therapies we offer.Even without trying, every night you go to bed a little wiser. Thanks for listening to Rio Bravo qWeek Podcast. We want to hear from you, send us an email at RioBravoqWeek@clinicasierravista.org, or visit our website riobravofmrp.org/qweek. See you next week! _____________________References:Chou, R., Qaseem, A., Snow, V., Casey, D., Cross, J. T., Shekelle, P., & Owens, D. K. (2007). Diagnosis and treatment of low back pain: A joint clinical practice guideline from the American College of Physicians and the American Pain Society. Annals of Internal Medicine, 147(7), 478–491. https://doi.org/10.7326/0003-4819-147-7-200710020-00006Deyo, R. A., Mirza, S. K., Turner, J. A., & Martin, B. I. (2009). Overtreating chronic back pain: Time to back off? Journal of the American Board of Family Medicine, 22(1), 62–68. https://doi.org/10.3122/jabfm.2009.01.080102National Institute for Health and Care Excellence. (2020). Low back pain and sciatica in over 16s: Assessment and management (NICE Guideline No. NG59). https://www.nice.org.uk/guidance/ng59Qaseem, A., Wilt, T. J., McLean, R. M., & Forciea, M. A. (2017). Noninvasive treatments for acute, subacute, and chronic low back pain: A clinical practice guideline from the American College of Physicians. Annals of Internal Medicine, 166(7), 514–530. https://doi.org/10.7326/M16-2367UpToDate. (n.d.). Evaluation and treatment of low back pain in adults. Wolters Kluwer. https://www.uptodate.com (Access requires subscription)Theme song, Works All The Time by Dominik Schwarzer, YouTube ID: CUBDNERZU8HXUHBS, purchased from https://www.premiumbeat.com/. 

As AI becomes more embedded in the daily lives of legal departments, the call for robustregulatory frameworks is louder than ever. In the 28th episode of Legal Leaders Exchange, wesit down with experts Ken Crutchfield and Jennifer McIver to explore the evolving landscapeof AI regulations—from the EU AI Act to global compliance trends. We unpack what thesechanges mean for legal professionals, compliance officers, and tech leaders, and howorganizations can proactively prepare for the future of AI governance.

Analizamos los valores clave en el Viejo Continente de la mano de Xavier Brun, responsable de RV europea de Trea AM. Vistazo a Nvidia, ASML, Besi, ST Micro y Wolters Kluwer.

In this episode of the Becker's Healthcare Podcast, Erika Spicer Mason speaks with Yaw Fellin, Vice President of Product and Solutions for Clinical Effectiveness at Wolters Kluwer Health, about how healthcare organizations can better leverage data and digital tools to drive improved patient outcomes. Yaw shares strategies for integrating data into meaningful clinical workflows, highlights the importance of harmonized patient education, and discusses the exciting role of AI and predictive analytics in advancing care efficiency and quality. Tune in to hear how leaders can navigate the evolving intersection of technology, decision support, and patient engagement.This episode is sponsored by Wolters Kluwer.

Welcome to another exciting episode of PICU Doc on Call! Today, we're diving deep into the world of pediatric critical care with our expert hosts, Dr. Rahul Damania, Dr. Pradip Kamat, and Dr. Monica Gray. Get ready to unravel the mysteries of the oxygen extraction ratio (O2ER) and its pivotal role in managing pediatric acute respiratory distress syndrome (ARDS) and multi-organ dysfunction.Picture this: a seven-year-old girl battling severe pneumonia that spirals into ARDS and septic shock. Our hosts walk you through this gripping case, shedding light on calculating O2ER and why central venous oxygen saturation (ScvO2) is a game-changer. They'll share their top strategies for optimizing oxygen delivery and cutting down on oxygen demand.But that's not all! This episode is all about the holistic approach to managing critically ill pediatric patients. Tune in to discover how these insights can lead to better outcomes for our youngest and most vulnerable patients. Don't miss out on this vital conversation!Show Highlights:Clinical significance of the oxygen extraction ratio (O2ER) in pediatric critical careImportance of understanding oxygen delivery and consumption in critically ill patientsCalculation and interpretation of O2ER and its relationship to central venous oxygen saturation (ScvO2)Physiological concepts related to oxygenation, including intrapulmonary shunting and ventilation-perfusion mismatchManagement strategies for increasing oxygen delivery and reducing oxygen demand in ARDS and septic shockInterventions such as blood transfusions, sedation, and optimization of cardiac outputImplications of lactic acidosis and anaerobic metabolism in the context of inadequate oxygen deliveryHolistic approach to patient management, focusing on both numerical values and overall metabolic needsWe welcome you to share your feedback, subscribe & place a review on our podcast! Please visit our website picudoconcall.org.References:Fuhrman B.P. & Zimmerman J.J. (Eds.). Pediatric Critical Care, 6th ed. Elsevier; 2021. (Key concepts of oxygen delivery, consumption, and extraction in shock states are discussed in Chapter 13) .Nichols D.G. (Ed.). Roger's Textbook of Pediatric Intensive Care, 5th ed. Wolters Kluwer; 2016. (Comprehensive review of oxygen transport and utilization in critically ill children, including ARDS and shock).Lucking S.E., Williams T.M., Chaten F.C., et al. Dependence of oxygen consumption on oxygen delivery in children with hyperdynamic septic shock and low oxygen extraction. Crit Care Med. 1990;18(12):1316–1319. doi:10.1097/00003246-199012000-00002.Ronco J.J., Fenwick J.C., Tweeddale M.G., et al. Pathologic dependence of oxygen consumption on oxygen delivery in acute respiratory failure. Chest. 1990;98(6):1463–1466. doi:10.1378/chest.98.6.1463 .Carcillo J.A., Davis A.L., Zaritsky A. Clinical practice parameters for hemodynamic support of pediatric and neonatal septic shock. Crit Care Med. 2002;30(6):1365–1378. (ACCM guidelines emphasizing ScvO₂ targets in shock) .Emeriaud G, López-Fernández YM, Iyer NP, et al; PALICC-2 Group; PALISI Network. Executive summary of the second international guidelines for the diagnosis and management of pediatric ARDS (PALICC-2). Pediatr Crit Care Med. 2023;24(2):143–168. doi:10.1097/PCC.0000000000003147.

In this episode of Technovation, Peter High speaks with Mark Sherwood, Chief Information Officer at Wolters Kluwer, a €6B global professional services and software firm headquartered in the Netherlands. Mark joined as CIO in December 2024 and has helped accelerate the company's transition from a traditional publishing business to a tech-centric organization. Mark discusses how his global team supports the company's AI- and cloud-first strategy, the role of business relationship managers (BRMs) in bridging tech and business, and how a strong innovation culture helps Wolters Kluwer stay ahead in the digital age. With nearly half the company's products leveraging AI and a robust multi-cloud foundation, the firm is redefining access to expert content in legal, tax, healthcare, and finance. Key topics include: Building a multi-cloud foundation for global resilience and innovation The evolution from a holding company to a unified operating mode Scaling AI across products while protecting intellectual property Driving cultural change through transparency, inclusion, and BRM alignment Balancing cutting-edge tech with ethical AI and data governance

Großer Po, schmale Taille, flacher Bauch – sieht so ein fitter Körper aus? Isa dachte das eine Zeit lang und hat dafür fast täglich trainiert. Dieses Fitness-Bild wurde ihr vor allem auf Social Media vermittelt. Was Fitsein bedeutet – und was nicht.**********Ihr hört: Gesprächspartnerin: Isa, hat lange im Gym auch für die Optik trainiert, jetzt ist sie beim Kickboxen Gesprächspartner: Sebastian Uhrich, Professor für Sportbetriebswirtschaftslehre, Deutsche Sporthochschule Köln Gesprächspartner: Ludwig Rappelt, Sportwissenschaftler, Institut für Trainingswissenschaften und Sportinformatik, Deutsche Sporthochschule Köln Autor und Host: Przemek Żuk Redaktion: Ivy Nortey, Lara Lorenz, Sarah Brendel, Friederike Seeger Produktion: Hermann Leppich**********Quellen:Wierzejska, R.A. (2021). Dietary Supplements—For Whom? The Current State of Knowledge about the Health Effects of Selected Supplement Use. Int. J. Environ. Res. Public Health 2021, 18(17), 8897.American College of Sports Medicine (2025). ACSM's Guidelines for Exercise Testing and Prescription. 12. Ausgabe. Wolters Kluwer.  **********Mehr zum Thema bei Deutschlandfunk Nova:Gesund statt exzessiv: Wie wir die passende Fitness-Routine findenGesunde Ernährung: Wie machen wir uns weniger Druck?Neujahrsvorsätze und Sport: Training muss Spaß machen, damit wir dranbleiben**********Den Artikel zum Stück findet ihr hier.**********Ihr könnt uns auch auf diesen Kanälen folgen: TikTok und Instagram .**********Meldet euch!Ihr könnt das Team von Facts & Feelings über Whatsapp erreichen.Uns interessiert: Was beschäftigt euch? Habt ihr ein Thema, über das wir unbedingt in der Sendung und im Podcast sprechen sollen?Schickt uns eine Sprachnachricht oder schreibt uns per 0160-91360852 oder an factsundfeelings@deutschlandradio.de.Wichtig: Wenn ihr diese Nummer speichert und uns eine Nachricht schickt, akzeptiert ihr unsere Regeln zum Datenschutz und bei Whatsapp die Datenschutzrichtlinien von Whatsapp.

"These are not the droids you're looking for." Just like Obi-Wan Kenobi used a simple phrase to shift the stormtroopers' perception, marketers need to pull off their own Jedi mind trick to capture mindshare for their brands. We call it "positioning."  In this episode, Drew Neisser is joined by Joe Cohen (AXIS), Sara Larsen (Wolters Kluwer), and Carlos Carvajal (Q2) to discuss the art and science of positioning—how to define, refine, and defend it in a crowded marketplace.  Key Discussion Points:  Joe Cohen explains how AXIS built credibility in energy transition by backing its positioning with real data.  Sara Larsen shares how Wolters Kluwer got internal teams on board with a major brand shift.  Carlos Carvajal reveals how Q2 overcame skepticism to expand beyond its core market.  What you'll learn:  ✔ How to use research to reinforce your brand's authority. ✔ Why positioning is an internal challenge before it's an external one. ✔ The role of analysts, customer feedback, and storytelling in shaping brand perception.  From using market research to create authority to ensuring internal teams embrace new positioning, this conversation is all about the strategies that make brands stand out—and stick!  For full show notes and transcripts, visit https://renegademarketing.com/podcasts/ To learn more about CMO Huddles, visit https://cmohuddles.com/

Watch The X22 Report On Video No videos found Click On Picture To See Larger PictureTrump is canceling the [CB] climate initiative and the funding. He is having Lee Zeldin reverse everything. [CB] trying to trap Trump, they will push for rate hike and Trump will call for a rate cut. Energy/Tariffs will counter it all. Gold is buying is surging. The [DS] is in a fit, their weapon is trying to convince the people that unelected Judges have the power to control the executive branch. Congress is preparing to show these Judges who has the real power. The [DS] is forcing the declas, boomerang. Trump has trapped them all, we are now entering the 15th round and the [DS] is exhausted from throwing punches at Trump, Trump is bringing it in the 15th round.   (function(w,d,s,i){w.ldAdInit=w.ldAdInit||[];w.ldAdInit.push({slot:13499335648425062,size:[0, 0],id:"ld-7164-1323"});if(!d.getElementById(i)){var j=d.createElement(s),p=d.getElementsByTagName(s)[0];j.async=true;j.src="//cdn2.customads.co/_js/ajs.js";j.id=i;p.parentNode.insertBefore(j,p);}})(window,document,"script","ld-ajs"); Economy US rescinds UN climate fund pledges  The US under former presidents Joe Biden and Barack Obama had pledged about $6bn combined to the GCF, with the most recent commitment announced at the Cop 28 climate talks in Dubai. But the two administrations were able to deliver only $2bn of the funding. The US has canceled about $4bn in pledged money to the UN's Green Climate Fund, the latest sign a sharp policy shift under President Donald Trump. The State Department late last week said the US "has rescinded outstanding pledges to the Green Climate Fund," but did not provide any further details. Source:  argusmedia.com   Trump tariffs to stoke inflation in 2025: corporate economists The gain in the Federal Reserve's preferred inflation measure will probably average nearly 2.7% during the four quarters starting in April, according to economists surveyed by Wolters Kluwer. Dive Brief: Eight out of 10 corporate economists forecast that U.S. tariffs will stoke inflation this year, Wolters Kluwer said Monday as the Trump administration intensified its shakeup of trade policy by threatening to impose 25% tariffs on steel and aluminum imports. Economists at companies ranging from Ford Motor Co. to Morgan Stanley and KPMG to Eaton Corp marked up their forecast for the increase in the consumer price index this year to 2.7% from 2.5% in October, Wolters Kluwer found in a survey. Source:  cfodive.com  https://twitter.com/KobeissiLetter/status/1889376017396937016 Why the Federal Reserve could shock the markets this summer: Economist If there is shock coming to markets, it could arrive this summer. And it could be in the form of a rate hike from the Federal Reserve. Sløk believes that should inflation accelerate as tariffs take hold, the first rate hike from the Fed could come at its mid-June meeting. More may follow, Sløk said, which could surprise a market that has settled into the view of the Fed standing pat on rates this year — if not lowering them further.  Sløk said the market hasn't priced in the prospect of rate hikes yet. Source: yahoo.com https://twitter.com/ShadowofEzra/status/1889022383584874690   interest, then pouring it into government bonds, creating the illusion that the government's financial situation is better than it actually is. He warns that this scheme isn't just limited to the U.S.—it's happening across central banks worldwide. https://twitter.com/KobeissiLetter/status/1889307554468987015   Political/Rights FBI “Just Discovered” 2,400 Undisclosed Records Tied to JFK Assassination Never Provided to Review Board The FBI has just “stumbled upon” a whopping 2,400 previously undisclosed records tied to the assassination of President...

Tiffany O'Donnell talks to Evette Creighton who is an Associate Director, Talent Management for Wolters Kluwer. In her role she provides talent management expertise to stakeholders within the Corporate Division. Prior to that, Evette was the Director of Talent, Inclusion and Diversity at Transamerica where she provided strategic direction and oversight to inclusion and diversity, talent review, succession planning, and performance management. Evette has over 15 years of Talent Management, Inclusion and Diversity experience. In her free time, Evette co-hosts a podcast, The Elevated Life Podcast, where she and her friend & co-host, Ashley, have real conversations, infectious laughter and share transformative growth experiences designed to elevate every aspect of their listeners' lives.On today's episode, Evette and Tiffany talk about the future of DEI, how they discuss it with their children and much more. Note: This episode was recorded in December 2024. Follow Women Lead Change on Facebook, Instagram and LinkedIn and visit wlcglobal.org for more information. Support the show

Language delays are one of the most common concerns brought up in pediatric well visits. Dr. Jennifer Poon, a pediatric specialist in Development and Behavior, joins Dr. Sarah Straka and medical student Alisha Patel to discuss how to recognize and manage language delays. Specifically, they will: Define and understand language delay. Recognize the initial signs and symptoms of language delays. Identify and explain clinical pearls of potential etiologies of language delays. Recognize the developmental milestones for language based on age. Discuss the prevalence of language delays as well as identify the risk factors and patient demographics that have an increased susceptibility. Understand the initial diagnostic approach to the child with suspected language delay. Review the most common interventions when a child has language delay. Understand how to best discuss the prognosis for language delays and counsel the families and caregivers CME Credit (requires free sign up):   link coming soon! References: Karani NF, Sher J, Mophosho M. The influence of screen time on children's language development: A scoping review. S Afr J Commun Disord. 2022 Feb 9;69(1):e1-e7. doi: 10.4102/sajcd.v69i1.825. PMID: 35144436; PMCID: PMC8905397. Law, James et al. “Speech and language therapy interventions for children with primary speech and/or language disorders.” The Cochrane Database of Systematic Reviews 2017,1 CD012490. 9 Jan. 2017, doi:10.1002/14651858.CD012490 Sices, Laura, and Marilyn Augustyn. “Expressive Language Delay (‘Late Talking') in Young Children.” Edited by Robert G Voigt and Mary Torchia, UptoDate, Wolters Kluwer, UpToDate, Inc., 25 Jan. 2022, https://www.uptodate.com/contents/expressive-language-delay-late-talking-in-young-children. Spratt, Eve G et al. “The Effects of Early Neglect on Cognitive, Language, and Behavioral Functioning in Childhood.” Psychology (Irvine, Calif.) 3,2 (2012): 175-182. doi:10.4236/psych.2012.32026 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3652241/ Sunderajan, Trisha, and Sujata V Kanhere. “Speech and language delay in children: Prevalence and risk factors.” Journal of family medicine and primary care 8,5 (2019): 1642-1646. doi:10.4103/jfmpc.jfmpc_162_19 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6559061/ Takahashi I, Obara T, Ishikuro M, et al. Screen Time at Age 1 Year and Communication and Problem-Solving Developmental Delay at 2 and 4 Years. JAMA Pediatr.Published online August 21, 2023. doi:10.1001/jamapediatrics.2023.3057 Young, Allen. and Matthew Ng. “Genetic Hearing Loss.” StatPearls, StatPearls Publishing, 17 April 2023. https://www.ncbi.nlm.nih.gov/books/NBK580517/ Zuckerman B, Khandekar A. Reach Out and Read: evidence based approach to promoting early child development. Curr Opin Pediatr. 2010 Aug;22(4):539-44. doi: 10.1097/MOP.0b013e32833a4673. PMID: 20601887.